Old Ayala, Inc financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
1313 N. Market Street, Suite 5100, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Former names
Ayala Pharmaceuticals, Inc. (to 1/19/2023)
Latest financial report
10-K - Q4 2022 - Mar 31, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275 % -66.2%
Return On Equity -309 %
Return On Assets -198 % -140%
Operating Margin -5.42K % -384%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.8M shares +6.35%
Common Stock, Shares, Outstanding 14.1M shares +0.89%
Entity Public Float 37.4M USD -18.7%
Common Stock, Value, Issued 139K USD 0%
Weighted Average Number of Shares Outstanding, Basic 15.4M shares +7.29%
Weighted Average Number of Shares Outstanding, Diluted 15.5M shares +6.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 692K USD -80.3%
Cost of Revenue 602K USD -82.8%
Research and Development Expense 27.9M USD -6.98%
General and Administrative Expense 9.74M USD +5.01%
Operating Income (Loss) -37.5M USD +4.37%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -37.4M USD +5.19%
Income Tax Expense (Benefit) 584K USD -24.7%
Net Income (Loss) Attributable to Parent -38M USD +5.57%
Earnings Per Share, Basic -2.46 USD/shares +12.1%
Earnings Per Share, Diluted -0.66 USD/shares +2.94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.41M USD -93.5%
Cash, Cash Equivalents, and Short-term Investments 11.5M USD
Assets, Current 3.19M USD -92%
Property, Plant and Equipment, Net 960K USD -14.3%
Operating Lease, Right-of-Use Asset 1.46M USD
Assets 7.77M USD -81.1%
Liabilities, Current 7.54M USD +16.4%
Operating Lease, Liability, Noncurrent 1.33M USD
Retained Earnings (Accumulated Deficit) -149M USD -34.2%
Stockholders' Equity Attributable to Parent -1.1M USD -103%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.1M USD -103%
Liabilities and Equity 7.77M USD -81.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.98M USD -3.47%
Net Cash Provided by (Used in) Financing Activities 44K USD -99.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 14.4M shares -2.91%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.94M USD -171%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.72M USD -92.7%
Deferred Tax Assets, Valuation Allowance 38.7M USD +32.4%
Deferred Tax Assets, Gross 39M USD +33.6%
Operating Lease, Liability 2.29K USD
Depreciation 30K USD -81.7%
Property, Plant and Equipment, Gross 1.62M USD +0.12%
Operating Lease, Liability, Current 419K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 345K USD -4.17%
Lessee, Operating Lease, Liability, to be Paid, Year One 445K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 375K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 309K USD -14.2%
Deferred Tax Assets, Operating Loss Carryforwards 27.6M USD +22%
Unrecognized Tax Benefits 1.32M USD +54.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 308K USD +157%
Additional Paid in Capital 148M USD +1.9%
Operating Leases, Future Minimum Payments, Due in Three Years 409K USD
Operating Leases, Future Minimum Payments Due 860K USD +2.38%
Interest Expense 5K USD +66.7%